Xiamen Amoytop Biotech Co Ltd banner
X

Xiamen Amoytop Biotech Co Ltd
SSE:688278

Watchlist Manager
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Watchlist
Price: 60.23 CNY -1.5% Market Closed
Market Cap: ¥24.6B

Xiamen Amoytop Biotech Co Ltd
Total Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Xiamen Amoytop Biotech Co Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Total Receivables
¥1.3B
CAGR 3-Years
73%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Receivables
¥6.3B
CAGR 3-Years
64%
CAGR 5-Years
61%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Total Receivables
¥1.7B
CAGR 3-Years
44%
CAGR 5-Years
29%
CAGR 10-Years
N/A
RemeGen Co Ltd
SSE:688331
Total Receivables
¥806.1m
CAGR 3-Years
38%
CAGR 5-Years
86%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Total Receivables
¥1B
CAGR 3-Years
38%
CAGR 5-Years
59%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Total Receivables
¥124.4m
CAGR 3-Years
6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Xiamen Amoytop Biotech Co Ltd
Glance View

Market Cap
24.6B CNY
Industry
Biotechnology

Xiamen Amoytop Biotech Co., Ltd., nestled in the heart of China's coastal city Xiamen, unfolds its narrative as a dynamic player in the biotechnology and healthcare industries. Born from an environment brimming with innovation, the company has diligently carved its niche by focusing on the research, development, and commercialization of diagnostic reagents and test kits. Its core competency lies in crafting solutions designed for precision and reliability, addressing the ever-evolving needs of laboratories and healthcare providers. Through a blend of cutting-edge technology and a keen understanding of biological complexities, Xiamen Amoytop has established itself as a reliable partner, providing essential tools that drive accurate diagnostics and improve patient outcomes across the globe. The company generates revenue by designing and delivering an extensive array of diagnostic products that are indispensable to modern medical practices. From infectious disease diagnostics to blood-based tests, Xiamen Amoytop leverages advancements in molecular biology to offer products that elevate the standards of health diagnostics. By supplying these critical products, the company ensures a steady flow of income sourced from healthcare facilities, research institutions, and diagnostic laboratories both domestically and internationally. Through its robust distribution network and focus on quality assurance, the company continues to expand its market presence, translating its technological prowess into financial growth and global impact.

Intrinsic Value
86.81 CNY
Undervaluation 31%
Intrinsic Value
Price ¥60.23
X

See Also

What is Xiamen Amoytop Biotech Co Ltd's Total Receivables?
Total Receivables
1.3B CNY

Based on the financial report for Dec 31, 2025, Xiamen Amoytop Biotech Co Ltd's Total Receivables amounts to 1.3B CNY.

What is Xiamen Amoytop Biotech Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 5Y
45%

Over the last year, the Total Receivables growth was 52%. The average annual Total Receivables growth rates for Xiamen Amoytop Biotech Co Ltd have been 73% over the past three years , 45% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett